Glaucoma Study Shows Brain Fights Against Degeneration
News Feb 27, 2018 | Original Story by Jessica Pasley for Vanderbilt University
A team of researchers, led by David Calkins, PhD, vice chair and director of Research at the Vanderbilt Eye Institute, has made a breakthrough discovery in the field of glaucoma showing new hopes for treatments to preserve vision.
In addition, Calkins is encouraged that the findings released in the Proceedings of the National Academy of Sciences (PNAS) will have treatment ramifications to combat age-related neurodegenerative disorders like Alzheimer’s and Parkinson’s diseases.
The paper, “Axogenic Mechanism Enhances Retinal Ganglion Cell Excitability During Early Progression in Glaucoma,” unmasked a revolutionary conclusion — in the past it was believed that as retinal activity is lost, the connection between the retina and the brain should be gone, but the opposite is true.
Calkins deemed the information one of the most significant discoveries since his team showed in 2010 that the first sign of injury in glaucoma occurs in the brain, and was similar to other age-related, central nervous system diseases.
“What we have demonstrated in our most recent study is that the brain fights back,” said Calkins, Denis O’Day Professor of Ophthalmology and Visual Sciences and director of the Vanderbilt Vision Research Center. “And we identified the mechanism for what causes this compensatory response. We found that for a brief period of time this particular mechanism actually preserves vision, despite the onslaught of stress in glaucoma.
“This is a real paradigm shift,” Calkins said. “The dogma has been that once started, neurodegenerative disease is a one-way path. But we found that individual neurons fight back to maintain signaling between brain regions, thereby slowing progression. It’s a balance between disease and adaptation.
“We think we can develop new therapies based on this mechanism to keep the optic nerve signaling, which will maintain vision even as a disease progresses.”
Diseases of the central nervous system involve early degradation of axon function that often precede degeneration — basically as the disease progresses, the retina stops talking to the brain, and soon afterward the axons begin to degenerate, then the retina and finally the brain, explained Calkins.
The team used a model of glaucoma, the leading cause of irreversible blindness in the world, to record and compare how the loss of synapses relates to the diminishment of signals to the axon.
Neurons have specialized projections called dendrites and axons. Dendrites bring information to the cell body and axons take information away from the cell body.
Information from one neuron flows to another neuron across a synapse.
In neurodegenerative disorders of the brain, those synapses are lost as the neuron dies.
Calkins’ team found that the axon signals did not diminish, rather the signaling to the brain increased, meaning that neurons were fighting back against the loss of excitatory activity.
“We discovered a sodium channel that usually sits far away from the cell body of the neuron,” Calkins said. “As the dendrites are lost, the sodium channel moves closer to the cell body and whatever residual activity remains, the channel boosts and amplifies the axon signal to the brain and for a brief period of time this mechanism actually preserves vision.”
“With this information, we hope to bootstrap this natural adaptive mechanism and prolong signaling between brain regions and prevent subsequent degeneration. As long as signaling is maintained, progression slows and vision is maintained.
“Now that we have identified the mechanism that causes adaptation, we can exploit it through new drugs or even gene therapy.”
This article has been republished from materials provided by Vanderbilt University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Risner, M. L., Pasini, S., Cooper, M. L., Lambert, W. S., & Calkins, D. J. (2018). Axogenic mechanism enhances retinal ganglion cell excitability during early progression in glaucoma. Proceedings of the National Academy of Sciences, 201714888.
Inter-areal Balanced Amplification Enhances Signal Propagation in the BrainNews
Neuroscientists find that signal transmission in a large-scale model of the primate brain is robust under the condition in which area-to-area connections exhibit a “balance” between excitation and inhibition.READ MORE
Early Life Experiences Alter DNA Structure in the Adult BrainNews
Scientists report in the journal Science that the type of mothering a female mouse provides her pups actually changes their DNA.READ MORE
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Comments | 1 ADD COMMENT
Sorice Madina | Mar 04, 2018
My husband will be 81 years old next month and was diagnosed with Parkinson's disease 13 months ago. his main symptom were and rigidity or stiffness of his right-hand side.he also had some difficulty writing. The original diagnosis was confirmed three months later by a second neurologist. He was on one tablet of pramipexole (Sifrol), 0.25 mg three times a day. Four months ago his neurologist added Biperiden, 2 mg. he takes half a tablet of Biperiden three times a day. Since the original diagnosis, his stiffness has slowly increased. He lost touch with reality. Suspecting it was the medication I took him off the Siferol (with the doctor’s knowledge) and started him on PD natural herbal formula we ordered from GREEN HOUSE HERBAL CLINIC, I spoke to few people who used the treatment here in Canada and they all gave a positive response, his symptoms totally declined over a 6 weeks use of the Green House Parkinson’s disease natural herbal formula. He is now almost 81 and doing very well, the disease is totally reversed! (Visit their website www . Greenhouseherbalclinic . com) I am thankful to nature, herbs are truly gift from God. Share with friends!!
International Conference on Neuroimmunology, Neurological disorders and Neurogenetics
Sep 26 - Sep 27, 2018